Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05019261
Other study ID # STUDY20110367
Secondary ID R01AG066731-01
Status Recruiting
Phase N/A
First received
Last updated
Start date November 11, 2021
Est. completion date April 30, 2026

Study information

Verified date March 2024
Source University of Pittsburgh
Contact Douglas B White, MD, MAS
Phone 412-864-3757
Email douglas.white@pitt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The National Academy of Medicine and the National Institutes of Health have called for urgent action to improve the care delivered to the nearly 1,000,000 older Americans who die in intensive care units (ICUs) annually or survive with substantial impairments. These patients often die with distressing symptoms and may receive more invasive, life-prolonging treatment than they would choose for themselves. Moreover, their family members acting as surrogate decision-makers often experience lasting psychological distress from the ICU experience. We will conduct a multicenter randomized trial among 370 incapacitated, critically ill older adult patients at high risk of death or severe functional impairment, their surrogate decision-makers, and their ICU clinicians to determine whether a multi-component family support intervention can improve the patient- and family-centeredness of care (primary outcome), as well as positively impact a variety of other patient, family, and healthcare delivery outcomes. The multicomponent intervention involves: Proactive family meetings scheduled within 48 hours of ICU admission and approximately every 5-7 days after that. Surrogates will have access (computer, tablet, or mobile phone) to the interactive web-based Family Support Tool. The tool will familiarize families with the ICU and prepare them for their interactions with the clinical team by completing specific sections of the Family Support Tool upon study enrollment, before family meetings, and any other time they wish. The ICU team will receive a tool-generated summary of information about the family before each family meeting, including their main questions and concerns, information about the patient's values and preferences, prognostic expectations, and unmet psychological needs.


Description:

The Family Support Tool intervention is designed to help families navigate the emotional, psychological, and cognitive complexities of being a surrogate for an incapacitated critically ill patient and also to enhance the timeliness and quality of clinician-family communication. The intervention consists of three components: 1. Proactive clinician-family meetings within 48 hours of enrollment and every 5-7 days thereafter. 2. Family members complete sections of an interactive web-based tool upon study enrollment, before family meetings, and any other time they wish. Family members can access the tool anywhere via computer, tablet, or mobile phone. The first section of the tool is completed on the first day of study enrollment and contains: video messages supporting families including stories from other families and their experiences and coping strategies, tips on self-care and links to hospital resources. The second and third sections of the FST are completed before scheduled clinician-family meetings on study day 2-3 and again 5-7 days later. These sections of the tool contain: videos detailing what to expect during family meetings, interactive exercises and prompts about patient values, prognosis, care expectations and treatment leanings to help prepare for family meetings. The study team will provide families a printed summary sheet of their main questions for the ICU team that they are encouraged to bring to the family meeting. 3. Before each scheduled family meeting the ICU team receives a written report that summarizes the family's main questions and concerns, information about the patient's values and preferences, surrogates' prognostic expectations, and a visual display of their unmet PC needs.


Recruitment information / eligibility

Status Recruiting
Enrollment 1163
Est. completion date April 30, 2026
Est. primary completion date April 30, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility INCLUSION Patient 1. Age =50 2. Lack of decision-making capacity as determined by clinical examination by the attending physician or designee 3. Clinical indication of at least 50% risk of death or =50% chance of new, severe long-term functional impairment (needs assistance with = 2 ADLs), as judged by the patient's attending physician or designee Surrogate 1. The primary surrogate is determined by the patient's advance directive or, if no directive exists, by following the hierarchy of surrogates codified in state law. 2. Up to 3 additional surrogates Clinician 1. Patient's primary attending (or their designee) EXCLUSION Patient 1. Lack of a surrogate decision maker 2. Family not available for study 3. Imminent death (within 24 hours); goals of care are already "comfort measures only"; decision to withdraw life support has already been made 4. Currently participating in a competing research study that does not allow co-enrollment 5. Incarcerated or on an involuntary hold 6. Died prior to enrollment 7. Discharged prior to enrollment 8. Regained capacity prior to enrollment 9. Physician declined patient's participation 10. Physician and designee declined own participation 11. Patient does not meet inclusion criteria within 3 days of ICU admission 12. MD expects transfer orders will be written or the patient will be transferred within 36 hours of screening Surrogate 1. Age <18 years 2. Cannot read or understand English 3. Cannot complete questionnaires due to physical or cognitive limitations 4. Has no access to or cannot travel to access the internet

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Multi-component Family Support Intervention
The multi-component intervention is designed to enhance the quality of clinician-family communication and help families manage the emotional and cognitive complexities of surrogate decision-making. It involves: 1) proactive clinician-family meetings; 2) use by surrogates of an interactive web-based tool throughout the ICU stay which is narrated by family members of ICU patients and includes stories and experiences from other families, self-care strategies, brief videos explaining what to expect during family meetings, a question prompt list, an interactive values clarification exercise, and an explanation of different treatment pathways for critically ill patients. 3. Prior to the proactive family meetings, the ICU team is provided with a summary of the family's main questions/concerns, their prognostic expectations, a summary of the patient's values and preferences, and surrogates' current ratings of the extent to which their psychosocial needs are being addressed in the ICU.

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Duke University Durham North Carolina
United States NYC Health + Hospitals/Lincoln Hospital New York New York
United States Pittsburgh VA Medical Center Pittsburgh Pennsylvania
United States University of Pittsburgh Pittsburgh Pennsylvania
United States Oregon Health and Science University Portland Oregon
United States Baystate Medical Center Springfield Massachusetts

Sponsors (8)

Lead Sponsor Collaborator
University of Pittsburgh Baystate Medical Center, Duke University, National Institute on Aging (NIA), New York City Health and Hospitals Corporation, Oregon Health and Science University, Pittsburgh VA Medical Center-University Drive, University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Patient hospital survival The vital status of the patient will be assessed at the conclusion of index hospitalization 6 months after hospital discharge
Other Duration of survival from hospital discharge through 6-month follow-up This will be measured as a time-to-event variable, with time 0 being the date of hospital discharge. All death dates will be confirmed by querying the SSDMF or institutional death indices at the completion of the trial. 6 months after hospital discharge
Other Days alive outside healthcare facilities We will calculate the number of days a patient was alive from discharge to 6 months, then subtract that from the number of days the patient was in a hospital, LTAC, SNF, rehab facility, or hospice. 6 months after hospital discharge
Other Patients' functional status Assessed using the Katz Index of Independence in Activities of Daily Living, a validated and widely-used scale to quantify patients' functional status. Katz is a 6-item (1 or 0 point) scale measuring independency in older adults. Lower scores indicate a greater level of dependence for measured skills. 6 months after hospital discharge
Primary Patient and family centeredness of care 12-item Patient Perceived Patient-Centeredness of Care Scale (PPPC), previously modified for use by surrogates, completed at 3-month telephone follow-up of surrogates. 3 months after hospital discharge
Secondary Composite measure of goal-concordant care Assessed by surrogates at 3-month telephone follow-up using an 8-item composite measure of goal-concordant care. 3 months after hospital discharge
Secondary Satisfaction with ICU care Assessed using the Family Satisfaction in the ICU (FS-ICU) instrument at 3-month telephone follow-up of surrogates. The FS-ICU is a 24-item scale concerning satisfaction with care, communication, and decision-making in the ICU. 3 months after hospital discharge
Secondary Unmet palliative care needs Measured using the adapted Needs of Social Nature, Existential Concerns, Symptoms, and Therapeutic Interaction (NEST) scale administered to surrogates on day 5 post-randomization. The adapted NEST scale is designed for ICU use; it is a 13-item instrument developed to identify unmet social, emotional, physical, and care-system needs in serious illness. Measured at day 5 post-randomization
Secondary Surrogates' prognostic awareness Assessed on study day 5 using the validated Clinician-Surrogate Concordance Scale (CSCS), which our research team developed. The single item CSCS has excellent test-retest reliability (r =0.91). It has established criterion validity and responsiveness to change. Measured at day 5 post-randomization
Secondary Surrogates' clarity about patient values and preferences Assessed by surrogates after family meetings on study day 5 using the "informed" and "values clarity" subscales, 6 items out of the 16-item Decisional Conflict Scale (DCS). The scale has established responsiveness to change, test-retest reliability (r=0.81), internal consistency (a=0.92), and discriminant validity. Measured at day 5 post-randomization
Secondary Clinician-family conflict A brief survey (measured by both surrogates and ICU clinicians) to determine the level of family-clinician conflict during index hospitalization Measured at day 5 post-randomization
Secondary Perceived effectiveness of Family Support Tool A brief survey asking (intervention only) surrogate participants perceived effectiveness of the FST intervention Measured at day 5 post-randomization
Secondary Risk of post-traumatic stress disorder Assessed using the Impact of Events Scale-revised (IES-R) at 6 months. The IES-R is a valid, reliable, and responsive 22 -item instrument measuring symptoms of avoidance and intrusive thoughts. A score 33 indicates a high risk of PTSD. It has been used successfully among ICU surrogates. 6 months after hospital discharge
Secondary Surrogates' symptoms of anxiety and depression The HADS is a 14-item, two-domain (anxiety, depression) instrument with established reliability and validity among ICU surrogates that is recommended by consensus guidelines for use among ICU surrogates. Assessed at 6-month telephone follow-up. 6 months after hospital discharge
Secondary Resource utilization Among hospital survivors we will perform interviews with surrogates at 3-months and 6-months to identify patient's post-discharge healthcare utilization (e.g. hospital admissions, ED visits, skilled-nursing facility use, hospice use, etc.), assigning costs using validated methods. 3 months and 6 months after hospital discharge
Secondary Proportion of patients with new DNR order during index hospitalization and time to first DNR order during index hospitalization 6 months after hospital discharge
Secondary Proportion of patients who received comfort-focused care during the index hospitalization and time to comfort-focused care 6 months after hospital discharge
Secondary Proportion of patients enrolled in hospice during index hospitalization 6 months after hospital discharge
Secondary ICU and hospital length of stay Duration of time patient spent in ICU and hospital 6 months after hospital discharge
Secondary Duration of mechanical ventilation Duration of time patient spent on mechanical ventilation during index hospitalization 6 months after hospital discharge
Secondary Cost of index hospitalization Assigning costs using validated methods, the cost of index hospitalization will be calculated 6 months after hospital discharge
Secondary Time to hospice time in days from enrollment to hospice 6 months after hospital discharge
See also
  Status Clinical Trial Phase
Completed NCT04551508 - Delirium Screening 3 Methods Study
Recruiting NCT06037928 - Plasma Sodium and Sodium Administration in the ICU
Completed NCT03671447 - Enhanced Recovery After Intensive Care (ERIC) N/A
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Recruiting NCT04674657 - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Completed NCT04239209 - Effect of Intensivist Communication on Surrogate Prognosis Interpretation N/A
Completed NCT05531305 - Longitudinal Changes in Muscle Mass After Intensive Care N/A
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Completed NCT02916004 - The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients. N/A
Recruiting NCT05883137 - High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
Completed NCT04479254 - The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study) N/A
Recruiting NCT04475666 - Replacing Protein Via Enteral Nutrition in Critically Ill Patients N/A
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Recruiting NCT02989051 - Fluid Restriction Keeps Children Dry Phase 2/Phase 3
Completed NCT02899208 - Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients? N/A
Completed NCT03048487 - Protein Consumption in Critically Ill Patients
Recruiting NCT02163109 - Oxygen Consumption in Critical Illness